ACT-903 conjugate demonstrated significant anti-tumor activity, with tumors becoming undetectable in 9 of 10 mice, and all 10 mice surviving through Day 60 with no obvious signs of toxicityACT’s technology highlights the potential to use the natural function of AFP as a carrier protein to deliver a payload uniquely.